Eli Lilly and Company – Consensus Indicates Potential 5.5% Upside

Eli Lilly and Co with the ticker code (LLY), 23 analysts have now covered the stock with a consensus rating of ‘Buy’. The target price is between 436 and 268. If we calculate the middle target price, we have 380.78. With the previous close at 360.88, this would suggest a potential upside of 5.5%. The 50-day MA is 338.86 and the 200-day MA is 307.77. The company has a market capitalization of $343,698 million. Company website: https://www.lilly.com

The potential market cap would be $362,651 million based on the market consensus.

You can now share this on Stocktwits, just click on the logo below and paste the ticker into the text to be seen.

Share on Stocktwits

Eli Lilly and Company discovers, develops and markets medicines for human use worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, Insulin Lispro, Insulin Lispro Protamin, Insulin Lispro Mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R and Humulin U-500 for diabetes; and Jardiance, Trajenta and Trulicity for type 2 diabetes. The company offers Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza in metastatic gastric cancer, gastroesophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer and hepatocellular carcinoma; Erbitux for colorectal cancer and various types of head and neck cancer; Retevmo in metastatic NSCLC, medullary thyroid cancer and thyroid cancer; Tyvyt for relapsed or refractory classical Hodgkin lymph and non-squamous NSCLC; and Verzenio for HR+, HER2-metastatic, lymph node-positive, and early-stage breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondylarthritis. The Company offers Cymbalta for major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia and chronic musculoskeletal pain; Emgality to prevent migraines and episodic cluster headaches; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. bamlanivimab and etesevimab and bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company works with Incyte Corporation; Boehringer Ingelheim Pharma; AbCellera Biologics Inc.; Junshi Life Sciences; Regor Therapeutics Group; Lycia therapeutics; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

READ :  Lack of causality entitles valve/seal defendant to summary judgment | Goldberg Segalla